BIOMAT Database Logo BIOMAT Database Logo

Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. 1996

J M Wilson, and K S Kalasinsky, and A I Levey, and C Bergeron, and G Reiber, and R M Anthony, and G A Schmunk, and K Shannak, and J W Haycock, and S J Kish
Human Neurochemical Pathology Laboratory, Clarke Institute of Psychiatry, Toronto, Ontario, Canada.

Methamphetamine is a drug that is significantly abused worldwide, Although long-lasting depletion of dopamine and other dopamine nerve terminal markers has been reported in striatum of nonhuman primates receiving very high doses of the psychostimulant, no information is available for humans. We found reduced levels of three dopamine nerve terminal markers (dopamine, tyrosine hydroxylase and the dopamine transporter) in post-mortem striatum (nucleus accumbens, caudate, putamen) of chronic methamphetamine users. However, levels of DOPA decarboxylase and the vesicular monoamine transporter, known to be reduced in Parkinson's disease, were normal. This suggests that chronic exposure to methamphetamine does not cause permanent degeneration of striatal dopamine nerve terminals at the doses used by the young subjects in our study. However, the dopamine reduction might explain some of the dysphoric effects of the drug, whereas the decreased dopamine transporter could provide the basis for dose escalation occurring in some methamphetamine users.

UI MeSH Term Description Entries
D008297 Male Males
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D008694 Methamphetamine A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed. Deoxyephedrine,Desoxyephedrine,Desoxyn,Madrine,Metamfetamine,Methamphetamine Hydrochloride,Methylamphetamine,N-Methylamphetamine,Hydrochloride, Methamphetamine,N Methylamphetamine
D009411 Nerve Endings Branch-like terminations of NERVE FIBERS, sensory or motor NEURONS. Endings of sensory neurons are the beginnings of afferent pathway to the CENTRAL NERVOUS SYSTEM. Endings of motor neurons are the terminals of axons at the muscle cells. Nerve endings which release neurotransmitters are called PRESYNAPTIC TERMINALS. Ending, Nerve,Endings, Nerve,Nerve Ending
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D009479 Neuropeptides Peptides released by NEURONS as intercellular messengers. Many neuropeptides are also hormones released by non-neuronal cells. Neuropeptide
D009714 Nucleus Accumbens Collection of pleomorphic cells in the caudal part of the anterior horn of the LATERAL VENTRICLE, in the region of the OLFACTORY TUBERCLE, lying between the head of the CAUDATE NUCLEUS and the ANTERIOR PERFORATED SUBSTANCE. It is part of the so-called VENTRAL STRIATUM, a composite structure considered part of the BASAL GANGLIA. Accumbens Nucleus,Nucleus Accumbens Septi,Accumbens Septi, Nucleus,Accumbens Septus, Nucleus,Accumbens, Nucleus,Nucleus Accumbens Septus,Nucleus, Accumbens,Septi, Nucleus Accumbens,Septus, Nucleus Accumbens
D011699 Putamen The largest and most lateral of the BASAL GANGLIA lying between the lateral medullary lamina of the GLOBUS PALLIDUS and the EXTERNAL CAPSULE. It is part of the neostriatum and forms part of the LENTIFORM NUCLEUS along with the GLOBUS PALLIDUS. Nucleus Putamen,Nucleus Putamens,Putamen, Nucleus,Putamens,Putamens, Nucleus
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic

Related Publications

J M Wilson, and K S Kalasinsky, and A I Levey, and C Bergeron, and G Reiber, and R M Anthony, and G A Schmunk, and K Shannak, and J W Haycock, and S J Kish
Decreased striatal dopamine D1 receptor-stimulated adenylyl cyclase activity in human methamphetamine users.
May 2003, The American journal of psychiatry,
J M Wilson, and K S Kalasinsky, and A I Levey, and C Bergeron, and G Reiber, and R M Anthony, and G A Schmunk, and K Shannak, and J W Haycock, and S J Kish
Markers associated with sex differences in methamphetamine-induced striatal dopamine neurotoxicity.
March 2011, Current neuropharmacology,
J M Wilson, and K S Kalasinsky, and A I Levey, and C Bergeron, and G Reiber, and R M Anthony, and G A Schmunk, and K Shannak, and J W Haycock, and S J Kish
Striatal dopamine nerve terminal markers but not nigral cellularity are reduced in spinocerebellar ataxia type 1.
April 1997, Neurology,
J M Wilson, and K S Kalasinsky, and A I Levey, and C Bergeron, and G Reiber, and R M Anthony, and G A Schmunk, and K Shannak, and J W Haycock, and S J Kish
Dopamine D1 receptor protein is elevated in nucleus accumbens of human, chronic methamphetamine users.
November 2000, Molecular psychiatry,
J M Wilson, and K S Kalasinsky, and A I Levey, and C Bergeron, and G Reiber, and R M Anthony, and G A Schmunk, and K Shannak, and J W Haycock, and S J Kish
Striatal dopaminergic and serotonergic markers in human heroin users.
May 2001, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
J M Wilson, and K S Kalasinsky, and A I Levey, and C Bergeron, and G Reiber, and R M Anthony, and G A Schmunk, and K Shannak, and J W Haycock, and S J Kish
MK-801 protection against methamphetamine-induced striatal dopamine terminal injury is associated with attenuated dopamine overflow.
June 1992, Synapse (New York, N.Y.),
J M Wilson, and K S Kalasinsky, and A I Levey, and C Bergeron, and G Reiber, and R M Anthony, and G A Schmunk, and K Shannak, and J W Haycock, and S J Kish
Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of human methamphetamine users.
May 2007, International journal of legal medicine,
J M Wilson, and K S Kalasinsky, and A I Levey, and C Bergeron, and G Reiber, and R M Anthony, and G A Schmunk, and K Shannak, and J W Haycock, and S J Kish
L-dopa pretreatment potentiates striatal dopamine overflow and produces dopamine terminal injury after a single methamphetamine injection.
October 1993, Brain research,
J M Wilson, and K S Kalasinsky, and A I Levey, and C Bergeron, and G Reiber, and R M Anthony, and G A Schmunk, and K Shannak, and J W Haycock, and S J Kish
Methamphetamine neurotoxicity: dissociation of striatal dopamine terminal damage from parietal cortical cell body injury.
December 1998, Synapse (New York, N.Y.),
J M Wilson, and K S Kalasinsky, and A I Levey, and C Bergeron, and G Reiber, and R M Anthony, and G A Schmunk, and K Shannak, and J W Haycock, and S J Kish
Low Striatal Dopamine D2-type Receptor Availability is Linked to Simulated Drug Choice in Methamphetamine Users.
March 2018, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Copied contents to your clipboard!